文献速递乳腺外科

三阴性乳腺癌治疗与结局的年龄差异:NCDB分析

Age disparities in triple-negative breast cancer treatment and outcomes: An NCDB analysis.
PubMed 文献 · Surgery · 2022-08-01

基于美国国家癌症数据库2005至2017年168,715例单侧三阴性乳腺癌女性,按年龄≤40、41-70、>70岁分层比较治疗与生存。≤40岁患者更高临床分期且更多接受新辅助化疗和乳房切除术,但乳房肿瘤反应更好;乳房切除加腋窝淋巴结清扫在各年龄组均与较差生存相关。

要点

  • ≤40岁三阴性乳腺癌患者更常见高临床分期并更多接受新辅助化疗。
  • ≤40岁患者更多行双侧乳房切除(37%),41-70岁和>70岁以部分乳房切除为主(48%、49%)。
  • 乳房切除加腋窝淋巴结清扫在各年龄组均与较差生存相关。

核心结论

  • 三阴性乳腺癌临床特征在年龄两端显著不同,可能驱动治疗决策;≤40岁患者虽因更晚期疾病合理接受新辅助化疗,但也接受更多不带来生存获益的广泛手术。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库识别2005至2017年接受治疗的单侧三阴性乳腺癌女性共168,715例,按年龄≤40、41-70、>70岁分层。

主要发现

  • 168,715例中16,287例(9.6%)≤40岁;≤40岁患者更高临床分期比例显著更高(P < .001),接受新辅助化疗比例显著更高(P < .001)。
  • ≤40岁患者最常见手术为双侧乳房切除(37%),41-70岁和>70岁最常见为部分乳房切除(分别为48%和49%)(P < .001)。
  • ≤40岁患者接受新辅助化疗和乳房切除的 odds ratio 均为1.5(均P < .05),尽管 youngest patients 乳房肿瘤反应更好。
  • 接受乳房切除加腋窝淋巴结清扫者相比部分乳房切除加前哨淋巴结活检者,在全部3个年龄组生存结局均更差(P < .001)。

临床怎么用

  • 对≤40岁三阴性乳腺癌患者,应关注其广泛手术(如双侧乳房切除)是否带来生存获益,避免仅因年龄因素选择更广泛手术。

局限性

  • 年龄差异是否源于肿瘤学因素或患者及提供者偏好尚需进一步研究确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Race, access to care, and molecular features result in outcome disparities in triple-negative breast cancer (TNBC). We sought to determine the role of age in TNBC disparity by hypothesizing that younger patients receive more comprehensive treatment, resulting in survival differences. METHODS: The National Cancer Database was used to identify women with unilateral TNBC treated from 2005 through 2017. Patients were stratified by age (≤40, 41-70, >70); demographics, clinical characteristics, and treatment factors were compared. Logistic regression determined factors associated with treatment received. Survival outcomes were analyzed using a stratified log-rank test. RESULTS: Of the 168,715 patients, 16,287 (9.6%) were ≤40 years. Patients ≤40 were significantly more likely to present at higher clinical stage (P < .001) and receive neoadjuvant chemotherapy (NAC, P < .001). Bilateral mastectomy was the most common surgery for patients ≤40 (37%), whereas partial mastectomy was most often used in patients 41 to 70 years old (48%) and those >70 (49%) (P < .001). Patients ≤40 years were significantly more likely to undergo both NAC and mastectomy than those >40 (odds ratio 1.5, both P < .05) despite a greater in-breast tumor response in the youngest patients. Patients treated with mastectomy and axillary lymph node dissection had inferior survival outcomes compared to those treated with partial mastectomy and sentinel lymph node biopsy across all 3 age groups (P < .001). CONCLUSION: The clinical characteristics of TNBC differ significantly at the extremes of age, likely driving treatment decisions. Although patients ≤40 present with a more advanced disease and appropriately receive NAC, they also undergo more extensive surgery that does not yield a survival benefit. Further research is needed to determine if age disparity is due to oncologic factors or patient and provider preferences.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Drapalik LM, Estes A, Sarode AL, et al. Age disparities in triple-negative breast cancer treatment and outcomes: An NCDB analysis. Surgery. 2022. PMID: 35927082. doi:10.1016/j.surg.2022.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。